fig1
Figure 1. Pathways inhibited by CB-839, nivolumab, cabozantinib and everolimus. GLS: glutaminase; GSH: glutathione; ATP: adenosine triphosphate; αKG: alpha-ketoglutarate; PD-1: programmed death receptor 1; PD-L1: programmed death ligand 1
Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Navigation
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
